Beam Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beam Therapeutics Inc.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Guide Therapeutics, Inc.